GE to sell BioPharma unit to Danaher for $21.4 billion

摘要

GE has signed a definitive agreement to sell its BioPharma business to Danaher,the global science and technology corporation.Expected to finalise in Q4 this year,the deal will see GE get $21 billion in cash.The agreed transaction,worth $21.4 billion,is not subject to a financing condition or a shareholder vote.”Today's transaction is a pivotal milestone,”said Lawrence Culp,Jr,GE Chairman and CEO,adding that it demonstrates that”we are executing on our strategy by taking thoughtful and deliberate action to reduce leverage and strengthen our balance sheet.”For Culp,the deal is a move to retain full flexibility for growth and strategic optionality with one of the world's leading healthcare companies.”We are pleased that our BioPharma colleagues will join a strong,established team at Danaher,”he enthused.